A run of wins and a warning: what ESMO 2026 means for the oncology industry

Five days of data did more than produce new treatment options. They raised the standard of evidence, sharpened the case for biomarker-led development, strengthened the ADC story and reinforced that both treatment intensification and de-escalation need to be driven by biology and robust evidence.

Now that ESMO 2026 has closed, the most useful question is not which abstract won the congress. It is what the full week tells us about where oncology development is moving. Across the three Presidential Symposia, positive phase 3 readouts dominated, including two Fortrea-managed studies, VOLGA and SAFFRON ^[1,2]. At the same time, the MOIO study, which tested less frequent immunotherapy dosing, did not show that this approach worked as well as standard dosing, suggesting that treatment de-escalation needs further investigation ^[3].

The wider ESMO program reinforced a common theme. Innovation is becoming more precise and more complex, but also harder to prove. Increasingly, the question is not simply whether a new approach works, but whether it can deliver a meaningful advantage for the right patients against an already effective standard of care.

Demonstrating that advantage is becoming more demanding, with tougher comparators, more precisely defined patient populations and, increasingly, longer follow-up to understand survival.

That is the thread we think matters for sponsors, CROs and investors. ESMO 2026 was not simply a story of more treatment. Across the congress, we saw treatment being intensified where there was clear benefit, established therapies being challenged by newer approaches, and treatment becoming more precisely matched to the biology of disease. We also saw important open questions about when treatment can safely be reduced.

Taken together, the direction feels less like “more treatment” and more like “better-matched treatment, supported by better evidence.”

Overall survival is back as the bar for success

One of the clearest messages from ESMO 2026 was the renewed importance of overall survival. The second Presidential Symposium brought this into focus, with KRASCENDO-1, SAFFRON, CLARITY-Gastric01 and HARMONi-GI1 all showing significant survival benefits ^[2,4–6]. What stood out was not simply that these studies were positive, but the standard against which success was judged. Several new treatments were tested against established therapies. CLARITY-Gastric01 also showed that endpoints do not always move together: it improved overall survival even though its progression-free survival endpoint did not reach statistical significance ^[5]. Later data added a note of caution. ARTEMIS-011 showed a strong progression-free survival benefit while overall survival was still immature ^[7]. KEYNOTE-C93 significantly improved progression-free survival, but interim overall survival had not yet met its prespecified significance threshold ^[8]. The takeaway is not that progression-free survival matters less. As treatment options improve, showing a durable, meaningful benefit that is ultimately reflected in survival will increasingly separate an encouraging result from a practice-changing one.

The comparator is becoming part of the innovation story

ESMO also showed how much harder it is becoming to demonstrate differentiation when effective treatments already exist. KRASCENDO-1 directly compared a next-generation KRAS G12C inhibitor with approved drugs targeting the same alteration ^[4], while HARMONi-GI1 tested ivonescimab plus chemotherapy against a current immunotherapy-based standard ^[6]. The significance is broader than either program: as oncology treatment improves, new entrants increasingly need to show a meaningful advantage over something that already works. For sponsors, that makes comparator choice, trial design and global execution part of the competitive strategy, not simply regulatory mechanics.

ADCs moved from a pipeline theme to a platform competition

Few modalities were as visible across ESMO as antibody-drug conjugates. Positive data extended across bladder, gastric, osteosarcoma and endometrial cancers, with programs such as VOLGA, CLARITY-Gastric01, ARTEMIS-011 and TroFuse-005 illustrating how quickly ADCs are moving across targets, tumor types and treatment settings^[1,5,7,9]. The more important shift, however, is that the field is moving beyond proving that the modality can work. With multiple ADCs now competing for attention, differentiation will increasingly depend on choosing the right target and population, finding the right place in the treatment sequence and balancing efficacy against class-specific and program-specific toxicity.

Personalization is broadening beyond a biomarker test

Personalization at ESMO went well beyond prescribing a targeted drug when a biomarker is present. INTerpath-001 brought individualized neoantigen therapy into the spotlight after melanoma surgery, with a treatment designed according to the unique mutational profile of each patient’s tumor^[10]. Other programs relied on increasingly specific molecular definitions, such as KRAS G12C, MET alteration and CLDN18.2 expression^[2,4,5]. Precision oncology is becoming as much an operational challenge as a scientific one. Finding the right patient now depends on access to testing and clear biomarker thresholds. For personalized therapies, it also depends on manufacturing and turnaround pathways that can deliver treatment when it is clinically needed.

De-escalation matters, but it has to be proven

One of the most useful counterpoints to ESMO’s positive results came from MOIO, which asked whether patients already benefiting from checkpoint inhibition could be treated less frequently. Reduced-frequency treatment did not establish progression-free survival non-inferiority, and the study was stopped early after an unexpected overall-survival imbalance favoring standard treatment^[3]. KEYNOTE-C93 approached treatment simplification differently, showing that pembrolizumab alone can produce a substantial progression-free survival benefit versus chemotherapy in first-line dMMR advanced or recurrent endometrial cancer, although it was not tested against the contemporary chemotherapy-plus-immunotherapy standard ^[8]. Together, these studies make a useful point: reducing treatment may be valuable, but it needs the same evidentiary discipline as adding treatment.

Earlier disease is becoming a proving ground for complex modalities

Another shift at ESMO was how often novel approaches appeared in settings where cure may still be possible. Examples include individualized therapy after melanoma surgery ^[10], the perioperative ADC–immunotherapy strategy evaluated in VOLGA in muscle-invasive bladder cancer ^[1], and treatment intensification in very high-risk localized prostate cancer ^[11]. Together, they move innovation earlier in the disease journey, and that changes the execution model. These studies depend more heavily on multidisciplinary sites, long-term follow-up and coordination across surgical, radiation oncology and systemic therapy teams. For personalized treatments, manufacturing and logistics become part of the clinical pathway rather than functions sitting alongside it.

China-generated evidence is now central to global oncology strategy

China-generated phase 3 evidence featured prominently in the ESMO program, including HARMONi-GI1 and ARTEMIS-011 ^[6,7]. The relevant industry question is not whether results generated in one geography should automatically translate elsewhere; they should not be assumed to. It is how early global development plans account for differences in patient populations, regulatory expectations, biomarker definitions and standards of care. China-originated development is increasingly part of the global oncology conversation, which makes bridging strategy something to design prospectively rather than solve after a positive readout.

Trial design itself is becoming a source of value

Perhaps the strongest cross-cutting lesson from ESMO is that scientific innovation and trial design are becoming harder to separate. Active-comparator studies, biomarker-selected populations, de-escalation questions and long-term survival follow-up each demand a different operational approach. For sponsors and CROs, the advantage therefore goes beyond recruiting faster. It lies in translating the scientific hypothesis into the right patients, comparator, countries, sites, assays, endpoints and follow-up plan, then executing those choices consistently enough for the result to be credible. SAFFRON is a good example. Its hypothesis, targeting MET-driven resistance after osimertinib, depended on identifying the right EGFR-mutated population with MET overexpression and amplification, and testing the targeted combination against chemotherapy ^[2].

What we would take into a 2027 oncology program

For a 2027 oncology program, the practical priorities are becoming clearer: plan early for durable outcomes and survival follow-up, expect stronger active comparators, build biomarker testing and screening yield into feasibility, consider China and global bridging as one development conversation and treat retention, multidisciplinary capability and logistics as critical-path decisions in early-stage or personalized studies. In crowded areas such as ADCs, differentiation and toxicity management need to be designed in from the outset, while de-escalation should be tested rather than assumed to preserve outcomes.

References

1. Powles T, et al. Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the phase 3 VOLGA trial. ESMO Congress 2026, Abstract LBA2.
2. [First author to confirm], et al. SAFFRON: savolitinib plus osimertinib versus platinum-based chemotherapy in EGFR-mutated, MET-overexpressed and/or amplified NSCLC after progression on osimertinib. ESMO Congress 2026, Abstract LBA6.
3. Gravis G, et al. MOIO: reduced-frequency versus standard immune checkpoint inhibitor dosing in patients with advanced or metastatic solid tumours responding to immunotherapy. ESMO Congress 2026, Abstract LBA10.
4. Skoulidis F, et al. Krascendo 1: divarasib versus sotorasib or adagrasib in previously treated KRAS G12C-mutated advanced NSCLC. ESMO Congress 2026, Abstract LBA5.
5. [First author to confirm], et al. CLARITY-Gastric01: sonesitatug vedotin versus investigator's choice in previously treated CLDN18.2-positive gastric or gastroesophageal junction cancer. ESMO Congress 2026, Abstract LBA7.
6. [First author to confirm], et al. HARMONi-GI1: ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer. ESMO Congress 2026, Abstract LBA8.
7. Xie L, et al. ARTEMIS-011: risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed or refractory osteosarcoma. ESMO Congress 2026, Abstract LBA9.
8. Slomovitz BM, et al. KEYNOTE-C93/GOG-3064/ENGOT-en15: first-line pembrolizumab versus carboplatin plus paclitaxel in mismatch repair-deficient advanced or recurrent endometrial cancer. ESMO Congress 2026, Abstract LBA12.
9. Lorusso D, et al. Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study. ESMO Congress 2026, Abstract LBA11.
10. Long GV, et al. INTerpath-001: intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab in resected high-risk melanoma. ESMO Congress 2026, Abstract LBA1.
11. Niazi T, et al. DASL-HiCaP (ANZUP1801): darolutamide with ADT and definitive or salvage locoregional radiation therapy for localised, very high-risk prostate cancer: interim analysis. ESMO Congress 2026, Abstract LBA4.

All references are late-breaking abstracts presented at the ESMO Congress 2026, Madrid, Spain, 23–27 October 2026.